LY 274601

Drug Profile

LY 274601

Latest Information Update: 01 Apr 1999

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anxiolytics; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Irritable bowel syndrome; Major depressive disorder; Male sexual dysfunction

Most Recent Events

  • 01 Apr 1999 No-Development-Reported for Anxiety disorders in USA (Unknown route)
  • 01 Apr 1999 No-Development-Reported for Depression in USA (Unknown route)
  • 01 Apr 1999 No-Development-Reported for Irritable bowel syndrome in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top